Log in

Relevant bibliographies by topics / Adderall / Journal articles

To see the other types of publications on this topic, follow the link: Adderall.

Journal articles on the topic 'Adderall'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Adderall.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

&NA;. "Adderall." Reactions Weekly &NA;, no. 1204 (2008): 5. http://dx.doi.org/10.2165/00128415-200812040-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Adderall." Reactions Weekly &NA;, no. 1077 (2005): 6. http://dx.doi.org/10.2165/00128415-200510770-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Adderall interaction." Reactions Weekly &NA;, no. 1174 (2007): 4. http://dx.doi.org/10.2165/00128415-200711740-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Adderall/methylphenidate." Reactions Weekly &NA;, no. 1177 (2007): 5. http://dx.doi.org/10.2165/00128415-200711770-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Moshirfar, Majid, Kayvon A. Moin, Muhammed Jaafar, Kenneth Han, Soroush Omidvarnia, and Phillip C. Hoopes. "Episodic Angle Closure after Visian™ Implantable Collamer Lens Implantation in a Patient Using Adderall^®." Case Reports in Ophthalmology 15, no. 1 (2024): 565–71. http://dx.doi.org/10.1159/000540080.

Full text

Abstract:

Introduction: Amphetamine-based medications such as Adderall®, used for the treatment of attention deficit-hyperactivity disorder (ADHD), may theoretically elicit angle closure through their adrenergic mechanisms. The relationship between the use of implantable collamer lenses (ICLs) and angle closure has been extensively investigated based on appropriate vault and lens sizing and postoperative changes in the anterior chamber angle (ACA) and corneal morphology. This case reflects a synergistic impact from both Adderall® use and ICL implantation for the proposed mechanism of angle closure. Case

APA, Harvard, Vancouver, ISO, and other styles

6

Stowe, Cindy D., Stephanie F. Gardner, Charles C. Gist, Eldon G. Schulz, and Thomas G. Wells. "24-Hour Ambulatory Blood Pressure Monitoring in Male Children Receiving Stimulant Therapy." Annals of Pharmacotherapy 36, no. 7-8 (2002): 1142–49. http://dx.doi.org/10.1345/aph.1a367.

Full text

Abstract:

OBJECTIVE: To determine whether cardiac indices are altered as assessed by 24-hour ambulatory blood pressure monitoring (ABPM) in male children receiving either chronic methylphenidate or dextroamphetamine/levoamphetamine (Adderall) therapy. METHODS: Boys 7–11 years old who were receiving methylphenidate or Adderall for a minimum of 2 months were asked to participate. Subjects wore ambulatory blood pressure monitors for 24-hour periods both off and on stimulant therapy. RESULTS: Subjects (n = 17; 8 methylphenidate, 9 Adderall) were well matched. Systolic blood pressure (SBP), diastolic blood p

APA, Harvard, Vancouver, ISO, and other styles

7

Vanga, Rohini R., Bikram Bal, and Kevin W. Olden. "Adderall Induced Acute Liver Injury: A Rare Case and Review of the Literature." Case Reports in Gastrointestinal Medicine 2013 (2013): 1–3. http://dx.doi.org/10.1155/2013/902892.

Full text

Abstract:

Adderall (dextroamphetamine/amphetamine) is a widely prescribed medicine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and is considered safe with due precautions. Use of prescribed Adderall without intention to overdose as a cause of acute liver injury is extremely rare, and to our knowledge no cases have been reported in the English literature. Amphetamine is an ingredient of recreational drugs such as Ecstacy and is known to cause hepatotoxicity. We describe here the case of a 55-year-old woman who developed acute liver failure during the treatment of ADHD with Addera

APA, Harvard, Vancouver, ISO, and other styles

8

Rose, Sherrill, Kristi S. Borowski, Wendy M. White, Matthew Hathcock, and Enid Rivera-Chiauzzi. "Adderall and Pregnancy." Obstetrics & Gynecology 131 (May 2018): 39S—40S. http://dx.doi.org/10.1097/01.aog.0000532976.17300.b9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Thomas, Stephanie, and Himanshu Upadhyaya. "ADDERALL AND SEIZURES." Journal of the American Academy of Child & Adolescent Psychiatry 41, no. 4 (2002): 365. http://dx.doi.org/10.1097/00004583-200204000-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

MCGOUGH, JAMES J., JOSEPH BIEDERMAN, LAURENCE L. GREENHILL, et al. "Pharmacokinetics of SLI381 (ADDERALL XR), an Extended-Release Formulation of Adderall." Journal of the American Academy of Child & Adolescent Psychiatry 42, no. 6 (2003): 684–91. http://dx.doi.org/10.1097/01.chi.0000046850.56865.cb.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

McKeage, Kate, and Lesley J. Scott. "SLI-381 (Adderall XR??)." CNS Drugs 17, no. 9 (2003): 669–75. http://dx.doi.org/10.2165/00023210-200317090-00006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Johnston, Charlotte. "SLI-381 (Adderall XR??)." CNS Drugs 17, no. 9 (2003): 676–77. http://dx.doi.org/10.2165/00023210-200317090-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ambrosini, Paul J. "SLI-381 (Adderall XR??)." CNS Drugs 17, no. 9 (2003): 676–77. http://dx.doi.org/10.2165/00023210-200317090-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Diller, Lawrence H. "ADDERALL AND THE FDA." Journal of the American Academy of Child & Adolescent Psychiatry 40, no. 7 (2001): 737. http://dx.doi.org/10.1097/00004583-200107000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Biron, P. "Questions about Adderall XR." Canadian Medical Association Journal 174, no. 9 (2006): 1303–4. http://dx.doi.org/10.1503/cmaj.1060004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Sikes, Carolyn, Jeffrey G. Stark, Russ McMahen, and Dorothy Engelking. "A Single-Dose, Two-Way Crossover, Open-Label Bioequivalence Study of an Amphetamine Extended-Release Oral Suspension in Healthy Adults." Journal of Attention Disorders 24, no. 3 (2017): 414–19. http://dx.doi.org/10.1177/1087054717743329.

Full text

Abstract:

Objective: The purpose of this study was to compare the pharmacokinetics of a new extended-release amphetamine oral suspension (AMP XR-OS) with a standard extended-release mixed amphetamine salts product, Adderall XR®. Method: In this single-dose, open-label, randomized, two-period, two-treatment crossover study, 42 healthy adult volunteers received 15 mL of AMP XR-OS in one period and a 30 mg Adderall XR capsule in another period (both containing 18.8 mg of amphetamine base) under fasted conditions. Blood samples were analyzed for d- and l-amphetamine concentrations, and pharmacokinetic param

APA, Harvard, Vancouver, ISO, and other styles

17

Millichap, J. Gordon. "Assessment of Adderall in ADHD." Pediatric Neurology Briefs 12, no. 5 (1998): 40. http://dx.doi.org/10.15844/pedneurbriefs-12-5-14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Health Canada Suspends Adderall Sales." Nurse Practitioner 30, no. 6 (2005): 66. http://dx.doi.org/10.1097/00006205-200506000-00024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Fitzgerald, Kevin T., and Alvin C. Bronstein. "Adderall® (Amphetamine-Dextroamphetamine) Toxicity." Topics in Companion Animal Medicine 28, no. 1 (2013): 2–7. http://dx.doi.org/10.1053/j.tcam.2013.03.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Splete, Heidi. "Health Canada Reinstates Adderall XR." Internal Medicine News 38, no. 21 (2005): 55. http://dx.doi.org/10.1016/s1097-8690(05)72279-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Splete, Heidi. "Health Canada Reinstates Adderall XR." Clinical Psychiatry News 33, no. 10 (2005): 8. http://dx.doi.org/10.1016/s0270-6644(05)70848-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

ALBUCHER, RONALD C., and GEORGE C. CURTIS. "Adderall for Obsessive-Compulsive Disorder." American Journal of Psychiatry 158, no. 5 (2001): 818—a—819. http://dx.doi.org/10.1176/appi.ajp.158.5.818-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Alsidawi, Said, James Muth, and James Wilkin. "Adderall induced inverted-Takotsubo cardiomyopathy." Catheterization and Cardiovascular Interventions 78, no. 6 (2011): 910–13. http://dx.doi.org/10.1002/ccd.23036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Allen, Shari N. "Adderall XR® and Vyvanse™." Mental Health Clinician 4, no. 1 (2014): 8–10. http://dx.doi.org/10.9740/mhc.n186948.

Full text

Abstract:

Adderall XR® (MAS XR) and Vyvanse™ (LDX) are both schedule II amphetamine-based central nervous system stimulants indicated for the treatment of attention-deficit/hyperactivity disorder. Differences among the two primarily involve dosage form, pharmacokinetic profiles, and abuse potential. MAS XR and LDX are both long-acting stimulants with an approximate duration of action of 10 hours. The long-acting property of LDX is secondary to its prodrug formulation, whereas MAS XR utilizes bead filled capsules that mimic twice daily dosing upon administration. MAS XR is a substrate of CYP 2D6 while LD

APA, Harvard, Vancouver, ISO, and other styles

25

Forrester, Mathias B. "Adderall Abuse in Texas, 1998–2004." Journal of Toxicology and Environmental Health, Part A 70, no. 7 (2007): 658–64. http://dx.doi.org/10.1080/15287390600974619.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Marks, Donald H. "Cardiomyopathy Due to Ingestion of Adderall." American Journal of Therapeutics 15, no. 3 (2008): 287–89. http://dx.doi.org/10.1097/mjt.0b013e3180ed6291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

MCNAMARA, DAMIAN. "Aczone Gel, 5% and Adderall XR." Pediatric News 39, no. 9 (2005): 45. http://dx.doi.org/10.1016/s0031-398x(05)70588-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Horrigan, Joseph P., L. Jarrett Barnhill, and R. Robin Kohli. "ADDERALL, THE ATYPICALS, AND WEIGHT GAIN." Journal of the American Academy of Child & Adolescent Psychiatry 40, no. 6 (2001): 620. http://dx.doi.org/10.1097/00004583-200106000-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

MCNAMARA, DAMIAN. "Aczone Gel 5% and Adderall XR." Family Practice News 35, no. 18 (2005): 31. http://dx.doi.org/10.1016/s0300-7073(05)71747-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Barkley, Russell. "Adderall XR Restored to Canadian Market." Child and Adolescent Psychopharmacology News 10, no. 4 (2005): 10. http://dx.doi.org/10.1521/capn.2005.10.4.10.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

McKenzie, Brook. "Does Adderall help attention deficit hyperactivity disorder?" Mental Health Weekly 32, no. 14 (2022): 5. http://dx.doi.org/10.1002/mhw.33175.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Gandhi, Pritesh J., Gladys U. Ezeala, Tuonglan T. Luyen, Tran C. Tu, and Maichi T. Tran. "Myocardial infarction in an adolescent taking Adderall." American Journal of Health-System Pharmacy 62, no. 14 (2005): 1494–97. http://dx.doi.org/10.2146/ajhp040220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Revised labelling for Adderall XR in Canada." Inpharma Weekly &NA;, no. 1504 (2005): 20. http://dx.doi.org/10.2165/00128413-200515040-00054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Revised labelling for Adderall XR in Canada." Reactions Weekly &NA;, no. 1068 (2005): 2. http://dx.doi.org/10.2165/00128415-200510680-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Sichilima, Tangu, and Michael J. Rieder. "Adderall and cardiovascular risk: A therapeutic dilemma." Paediatrics & Child Health 14, no. 3 (2009): 193–95. http://dx.doi.org/10.1093/pch/14.3.193.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Brunk, Doug. "Health Canada Suspends Sale of Adderall XR." Internal Medicine News 38, no. 6 (2005): 67. http://dx.doi.org/10.1016/s1097-8690(05)70222-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Splete, Heidi. "Adderall XR Gets Indication for Adolescent ADHD." Clinical Psychiatry News 33, no. 8 (2005): 11. http://dx.doi.org/10.1016/s0270-6644(05)70574-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Gaudiano, Maria Cristina, Anna Borioni, Eleonora Antoniella, and Luisa Valvo. "Counterfeit Adderall Containing Aceclofenac from Internet Pharmacies." Journal of Forensic Sciences 61, no. 4 (2016): 1126–30. http://dx.doi.org/10.1111/1556-4029.13095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "??? but benefits of ???Adderall??? may be longer lasting." Inpharma Weekly &NA;, no. 1185 (1999): 15. http://dx.doi.org/10.2165/00128413-199911850-00028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Innes, Carmen. "???Adderall??? gets all the attention in ADHD studies." Inpharma Weekly &NA;, no. 1195 (1999): 13–14. http://dx.doi.org/10.2165/00128413-199911950-00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Millichap, J. Gordon. "Randomized, Controlled Study of Adderall XR in ADHD." Pediatric Neurology Briefs 16, no. 8 (2002): 64. http://dx.doi.org/10.15844/pedneurbriefs-16-8-13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Millichap, J. Gordon. "Long-Term Effects of Adderall XR in ADHD." Pediatric Neurology Briefs 19, no. 6 (2005): 48. http://dx.doi.org/10.15844/pedneurbriefs-19-6-10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "???Adderall??? for ADHD and hypersomnia in the US." Inpharma Weekly &NA;, no. 1027 (1996): 22. http://dx.doi.org/10.2165/00128413-199610270-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Health Canada suspends Adderall, US FDA advises caution." Inpharma Weekly &NA;, no. 1475 (2005): 20. http://dx.doi.org/10.2165/00128413-200514750-00049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Adderall XR allowed back on the Canadian market." Inpharma Weekly &NA;, no. 1503 (2005): 21. http://dx.doi.org/10.2165/00128413-200515030-00053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

&NA;. "Health Canada suspends Adderall, US FDA advises caution." Reactions Weekly &NA;, no. 1039 (2005): 2. http://dx.doi.org/10.2165/00128415-200510390-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

&NA;. "Adderall XR allowed back on the Canadian market." Reactions Weekly &NA;, no. 1067 (2005): 2. http://dx.doi.org/10.2165/00128415-200510670-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Kondro, W. "Inconclusive evidence puts Adderall back on the market." Canadian Medical Association Journal 173, no. 8 (2005): 858. http://dx.doi.org/10.1503/cmaj.051145.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Diller, Lawrence H. "ASSESSMENT OF ADDERALL* IN ADHD: To the Editor." Journal of the American Academy of Child & Adolescent Psychiatry 38, no. 1 (1999): 2. http://dx.doi.org/10.1097/00004583-199901000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Cody, J. T., S. Valtier, and S. L. Nelson. "Amphetamine Enantiomer Excretion Profile Following Administration of Adderall." Journal of Analytical Toxicology 27, no. 7 (2003): 485–92. http://dx.doi.org/10.1093/jat/27.7.485.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!